Hussman Strategic Advisors’s AnaptysBio ANAB Stock Holding History

Hussman Strategic Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Hold	21,000	–	–	0.33%	147
2026 Q1	$1.16M	Buy	+21,000	New	+$1.13M	0.25%	180

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Hussman Strategic Advisors's ANAB Position: Q2 2026 in Review

Hussman Strategic Advisors held its AnaptysBio (ANAB) position steady in Q2 2026 at 21,000 shares worth $1.42M. The position accounts for 0.33% of the portfolio, ranked #147.

Hussman Strategic Advisors first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Hussman Strategic Advisors held 21,000 shares of AnaptysBio worth $1.42M as of Q2 2026.
Hussman Strategic Advisors left its AnaptysBio share count unchanged in Q2 2026.
AnaptysBio made up 0.33% of Hussman Strategic Advisors's portfolio in Q2 2026, its #147 holding.
Hussman Strategic Advisors first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.